Amalgamated Bank Fate Therapeutics Inc Transaction History
Amalgamated Bank
- $11.7 Billion
- Q1 2025
A detailed history of Amalgamated Bank transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Amalgamated Bank holds 2,912 shares of FATE stock, worth $3,902. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,912
Previous 2,912
-0.0%
Holding current value
$3,902
Previous $5,000
60.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding FATE
# of Institutions
144Shares Held
97MCall Options Held
56.7KPut Options Held
5.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$17.2 Million1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$13.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$13.6 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$10.4 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$5.75 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $130M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...